Invention Grant
- Patent Title: Furin inhibitors
-
Application No.: US17054491Application Date: 2019-05-10
-
Publication No.: US11773078B2Publication Date: 2023-10-03
- Inventor: Jeffrey Michael Axten , Mui Cheung , Michael P. Demartino , Huiping Amy Guan , Yan Hu , Aaron Bayne Miller , Donghui Qin , Chengde Wu , Zhiliu Zhang , Xiaojuan Lin
- Applicant: Glaxosmithkline Intellectual Property Development Limited
- Applicant Address: GB Brentford
- Assignee: Glaxosmithkline Intellectual Property Development Limited
- Current Assignee: Glaxosmithkline Intellectual Property Development Limited
- Current Assignee Address: GB Brentford
- Agency: Wolf, Greenfield & Sacks, P.C.
- International Application: PCT/EP2019/062098 2019.05.10
- International Announcement: WO2019/215341A 2019.11.14
- Date entered country: 2020-11-10
- Main IPC: C07D401/12
- IPC: C07D401/12 ; C07D401/14 ; A61P11/00 ; C07D211/26 ; C07D487/08

Abstract:
This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.
Public/Granted literature
- US20220315556A1 FURIN INHIBITORS Public/Granted day:2022-10-06
Information query